|View printer-friendly version|
Array BioPharma Appoints John L. Zabriskie Ph.D. to Its Board of Directors
BOULDER, Colo., Jan. 4 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the appointment of John L. Zabriskie, Ph.D., a former president and CEO of Pharmacia Upjohn, to its Board of Directors. This is a new board appointment, bringing the total number of board members to nine.
Dr. Zabriskie is past chairman of the board, chief executive officer and president of NEN Life Science Products Inc., a privately held manufacturer of kits for labeling and detection of DNA. Perkin Elmer Instruments acquired NEN in 2000. Prior to joining NEN Life Science Products, Dr. Zabriskie was president and chief executive officer of Pharmacia Upjohn Inc. As chairman of the board and chief executive officer of the Upjohn Company, Dr. Zabriskie led the merger of Upjohn with Pharmacia. Prior to joining Upjohn in 1994, Dr. Zabriskie was executive vice president of Merck and Co.
"We are delighted that Dr. Zabriskie has agreed to join the Array board of directors," said Kyle Lefkoff, chairman of the board of directors for Array. "As a chemist and a senior executive, Dr. Zabriskie is a proven leader in the pharmaceutical industry. His knowledge and experience will be a complementary addition to our board."
"I am pleased to have the opportunity to contribute to the growth of Array BioPharma," said Dr. Zabriskie. "This young company has accomplished a great deal so far, and I look forward to being part of the team going forward."
Array BioPharma, Inc., is a discovery research company creating drug candidates through innovations in chemistry. Array combines innovations in drug discovery technology with products and services to create, evaluate and optimize potential drug candidates in collaboration with pharmaceutical and biotechnology companies. For additional information, visit the company's web site at www.arraybiopharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed below and described more fully in reports filed by Array with the Securities and Exchange Commission, including our final prospectus as filed on November 16, 2000. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with third parties on their drug discovery activities and our ability to attract and retain experienced scientists and management. We are providing this information as of January 4th, 2001. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements. SOURCE Array BioPharma Inc.
CONTACT: Joanna K. Money, Ph.D. of Array BioPharma Inc., 303-381-6676, email@example.com/